Fedratinib
A Phase 2 Study of Fedratinib in Myelodysplastic /Myeloproliferative Neoplasms (MDS/MPNs) and Chronic Neutrophilic Leukemia (CNL)
More Information
- Trial Status
- Accepting patients
- Trial Phase
- Phase 2
- Enrollment
- 25 patients (estimated)
- Sponsors
- Moffitt Cancer Center
- Collaborators
- Bristol Myers Squibb
- Tags
- JAK2 Inhibitor, Kinase Inhibitor
- Trial Type
- Treatment
- Last Update
- 2 weeks ago
- SparkCures ID
- 1880
- NCT Identifier
- NCT05177211
Real People. Real Support.
Need help connecting with this clinical trial? We're here to help!
Print this trial to share with your doctor.
We can help answer any questions and connect you (or your patient) with the study team.
Schedule a time that is convenient and we’ll call you to see how we can help you and your patient.